SC
IOVA icon

Stephens Consulting’s Iovance Biotherapeutics IOVA Stock Holding History

Stephens Consulting’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110
Closed -$367 – 1576
2025
Q1 		$367 Buy
+110
New +$567 ﹤0.01% 1222

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stephens Consulting's IOVA Position: Q2 2025 in Review

Stephens Consulting sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 110 shares — an estimated $367 sold.

Stephens Consulting first reported a position in IOVA in Q1 2025 and held it in 1 quarter. The position peaked at $367 in Q1 2025. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Stephens Consulting reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 110 Iovance Biotherapeutics shares in Q2 2025, an estimated $367.
  • Stephens Consulting first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Iovance Biotherapeutics position peaked at $367 in Q1 2025.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.